Wealth Enhancement Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.24M	Sell	7,494 -984	-12%	-$297K	﹤0.01%	1497
2026 Q1	$2.7M	Sell	8,478 -5,609	-40%	-$1.91M	0.01%	1230
2025 Q4	$5.74M	Sell	14,087 -438	-3%	-$194K	0.01%	950
2025 Q3	$6.68M	Buy	14,525 +9,407	+184%	+$3.83M	0.01%	821
2025 Q2	$1.7M	Sell	5,118 -9,286	-64%	-$2.57M	﹤0.01%	1443
2025 Q1	$3.89M	Buy	14,404 +1,838	+15%	+$472K	0.01%	916
2024 Q4	$2.96M	Buy	12,566 +6,112	+95%	+$1.61M	0.01%	1003
2024 Q3	$1.77M	Buy	6,454 +2,323	+56%	+$605K	﹤0.01%	1117
2024 Q2	$1M	Buy	4,131 +1,184	+40%	+$187K	﹤0.01%	1275
2024 Q1	$440K	Buy	2,947 +548	+23%	+$91.4K	﹤0.01%	1658
2023 Q4	$459K	Buy	2,399 +216	+10%	+$36.8K	﹤0.01%	1558
2023 Q3	$387K	Buy	+2,183	New	+$416K	﹤0.01%	1588
2020 Q3	–	Sell	-8,758	Closed	-$1.38M	–	206
2020 Q2	$1.38M	Buy	+8,758	New	+$1.18M	0.04%	159

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealth Enhancement Advisory Services's ALNY Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q2 2026, selling an estimated $297K and leaving 7,494 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Wealth Enhancement Advisory Services first reported a position in ALNY in Q2 2020 and has held it in 13 quarters since. The position peaked at $6.68M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Wealth Enhancement Advisory Services held 7,494 shares of Alnylam Pharmaceuticals worth $2.24M as of Q2 2026.
Wealth Enhancement Advisory Services sold 984 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $297K.
Alnylam Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #1497 holding.
Wealth Enhancement Advisory Services first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
Wealth Enhancement Advisory Services's Alnylam Pharmaceuticals position peaked at $6.68M in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.